ALK Positive Australia is sharing a worldwide patient survey from Oncogene Cancer Research, a UK patient charity, exploring how lung cancer treatment, whether tablets or IV infusions, affects work, family life, independence and everyday wellbeing.
The survey aims to give patients’ experiences and preferences a stronger voice in decisions about new treatments and access to them.
Why does this matter for Australia?
Australia faces many of the same challenges in assessing and funding new cancer treatments. With enough responses from Australian patients, the findings could provide valuable evidence to support patient advocacy and inform discussions about treatment access, health technology assessments and reimbursement.
Oncogene Cancer Research has offered to share the aggregated Australian findings with patient organisations to support this work.
Who can participate?
The survey is open worldwide to people living with lung cancer, across all biomarker groups, including ALK+. Caregivers and care partners can also respond on someone’s behalf.
- Takes just 10–15 minutes
- Completely anonymous
- Participation is voluntary
Please share with others in the lung cancer community. Your experience matters, and your voice deserves a place in decisions about cancer treatments.
